Anal Cancer - Pipeline Review, H1 2018

  • ID: 4464933
  • Report
  • 237 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • BeiGene Ltd
  • Eli Lilly and Co
  • Immunovaccine Inc
  • Merck & Co Inc
  • Novan Inc
  • MORE
Anal Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H1 2018, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 6 and 5 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • BeiGene Ltd
  • Eli Lilly and Co
  • Immunovaccine Inc
  • Merck & Co Inc
  • Novan Inc
  • MORE
Introduction

Anal Cancer - Overview

Anal Cancer - Therapeutics Development

Anal Cancer - Therapeutics Assessment

Anal Cancer - Companies Involved in Therapeutics Development

Anal Cancer - Drug Profiles

Anal Cancer - Dormant Projects

Anal Cancer - Discontinued Products

Anal Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Anal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Anal Cancer - Pipeline by Advaxis Inc, H1 2018

Anal Cancer - Pipeline by Bayer AG, H1 2018

Anal Cancer - Pipeline by BeiGene Ltd, H1 2018

Anal Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Anal Cancer - Pipeline by Eli Lilly and Co, H1 2018

Anal Cancer - Pipeline by Genentech Inc, H1 2018

Anal Cancer - Pipeline by Immunovaccine Inc, H1 2018

Anal Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2018

Anal Cancer - Pipeline by Merck & Co Inc, H1 2018

Anal Cancer - Pipeline by Merck KGaA, H1 2018

Anal Cancer - Pipeline by Novan Inc, H1 2018

Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Anal Cancer - Pipeline by PDS Biotechnology Corp, H1 2018

Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Anal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2018

Anal Cancer - Pipeline by Transgene SA, H1 2018

Anal Cancer - Dormant Projects, H1 2018

Anal Cancer - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Anal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advaxis Inc
  • Bayer AG
  • BeiGene Ltd
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Genentech Inc
  • Immunovaccine Inc
  • ISA Pharmaceuticals BV
  • Merck & Co Inc
  • Merck KGaA
  • Novan Inc
  • Ono Pharmaceutical Co Ltd
  • PDS Biotechnology Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll